Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon5 and 2 bp insertion in exon5.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-KDM7A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
JHDM1D also known as KDM7A is a histone demethylase enzyme involved in the removal of methyl groups from di- and trimethylated lysine residues on histone tails particularly at H3K9 and H3K27. This action impacts gene expression by altering chromatin structure making it an important player in regulating transcriptional activities. The target has a molecular mass of approximately 129 kDa. JHDM1D is widely expressed in various tissues with notably high expression levels in the brain and testis indicating its importance in these organs.
Biological function summary
JHDM1D functions as part of a larger protein complex that regulates chromatin remodeling and gene expression. It plays a significant role in epigenetic modification processes influencing cell differentiation and development through its demethylation activity. Such capabilities affect cellular proliferation and lineage specification and may impact immune responses and neurological functions.
Pathways
Epigenetic regulation and chromatin remodeling see direct involvement from JHDM1D through pathways including the histone modification pathway and Wnt signaling pathway. In these pathways JHDM1D interacts with related proteins like EZH2 which also takes part in chromatin modifications and transcriptional control. This interplay highlights the importance of JHDM1D in fine-tuning gene expression.
Altered JHDM1D function relates to cancer progression and multiple neurological disorders. Dysregulation of this protein may contribute to abnormal cell growth and development as seen in certain cancers. Additionally its interactions with proteins like p53 suggest a potential role in tumor suppression pathways. In neurological disorders JHDM1D's impact on brain-specific gene expression may underline deficits seen in conditions like autism spectrum disorders.
